

Applicants: POHLNER *et al.*

Application No.: 10/520,679 (*U.S. Nat'l Phase of PCT/EP03/07361*)

Filed: I.A. Filing Date: July 9, 2003

For: Diagnostic and Therapeutic Use of a Rab Family GTP-Binding Protein for Neurodegenerative Diseases

Due Date: October 2, 2005

Art Unit: *To be assigned*

Confirmation No.: 7233

Examiner: *To be assigned*

Docket: 2335.0030001

Atty: SRL/KPQ

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Submission Under 35 U.S.C. § 371
2. Copy of Notification of Missing Requirements Under 35 U.S.C. § 371 in the United States Designated/Elected Office (DO/EO/US);
3. Original Declaration for Patent Application, executed by inventors;
4. Power of Attorney from Assignee with Delegation;
5. Statement Under 37 C.F.R. § 3.73(b) with copy of Assignment attached;
6. Return postcard; and
7. Credit Card Payment Form PTO-2038 in the amount of \$1,330.00 to cover \$1,200.00 Excess claims fee; and \$130.00 Surcharge for late filing of Declaration.



Mail Stop: PCT

Please Date Stamp and Return to Our Courier

449957_1.DOC

10/50679

2023712540

P.09

Rec'd PCT/PTO 13 OCT 2005

Declaration for Patent Application

Docket Number: 2335.0030001/SRL/KPQ

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter that is claimed and for which a patent is sought on the invention entitled **Diagnostic and Therapeutic Use of a Rab Family GTP-Binding Protein for Neurodegenerative Diseases**, the specification of which is attached hereto unless the following box is checked:

was filed on July 9, 2003;
 as United States Application Number or International Application Number PCT/EP03/07361; and
 was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or (f) or § 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or § 365(a) of any PCT international application, which designated at least one country other than the United States of America, listed below, and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Applications(s):

Priority Claimed

<u>02015429.0</u> (Application No.)	<u>EP</u> (Country)	<u>11 July 2002</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
--	------------------------	---	---	-----------------------------

Send Correspondence to: **STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.**
 1100 New York Avenue, N.W.
 Washington, D.C. 20005-3934

Direct Telephone Calls to: **(202) 371-2600**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

10/50679

202312540

P 10

Rec'd PCT/PTO

Q3 OCT 2005

U.S. Nat'l Phase of PCT/EP03/007361
Docket No. 2335.0030001/SRL/KPQ

Full name of first Inventor:	Johannes POHLNER
Signature of first Inventor:	
Residence:	Hamburg, GERMANY 
Citizenship:	German
Mailing Address:	Quittenweg 11 Hamburg, Germany 22175

Full name of second Inventor:	Heinz VON DER KAMMER
Signature of second Inventor:	
Residence:	Hamburg, GERMANY 
Citizenship:	German
Mailing Address:	Verbindungsstr. 6d Hamburg, Germany 22607

347639-1

10/320679

2023712540

P.11

Rec'd PCT/PTO 23 OCT 2005

POWER OF ATTORNEY FROM ASSIGNEE WITH DELEGATION

Evotec Neurosciences GmbH, a corporation of Germany, having a principal place of business at Schnackenburgallee 114, Hamburg, GERMANY 22525, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on 1) March 15, 2005 2) March 15, 2005 of an invention known as Diagnostic and Therapeutic Use of a Rab Family GTP-Binding Protein for Neurodegenerative Diseases (Attorney Docket No. 2335.0030001/SRL/KPQ), that is disclosed and claimed in a patent application of the same title by the inventors Johannes POHLNER and Heinz VON DER KAMMER (said application filed at the U.S. Patent and Trademark Office as U.S. national phase of PCT/EP03/07361, international filing date July 9, 2003).

For the purpose of PAIR, the Customer Number is 26111.

The Assignee hereby appoints the U.S. attorneys associated with CUSTOMER NUMBER 28393 to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith. The Assignee hereby grants said attorneys associated with Customer Number 28393 the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

The Assignee hereby authorizes the U.S. attorneys named herein to accept and follow instructions from von Kreisler Selting Werner as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the Assignee. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the Assignee.

Send correspondence to:

Customer Number 26111
 STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
 1100 New York Avenue, N.W.
 Washington, D.C. 20005-3934
 U.S.A.

Direct phone calls to 202-371-2600.

FOR: Evotec Neurosciences GmbH
 SIGNATURE: Johannes Pohlner
 BY: Johannes Pohlner
 TITLE: Managing Director
 DATE: 16 March 2005